Suppr超能文献

镰状细胞肾病:病理生理学、诊断及治疗的最新进展

Sickle cell nephropathy: an update on pathophysiology, diagnosis, and treatment.

作者信息

Hariri Essa, Mansour Anthony, El Alam Andrew, Daaboul Yazan, Korjian Serge, Aoun Bahous Sola

机构信息

Cardiovascular Medicine, Department of Internal Medicine, University of Massachusetts Medical School, Worcester, MA, USA.

Lebanese American University School of Medicine, Byblos, Lebanon.

出版信息

Int Urol Nephrol. 2018 Jun;50(6):1075-1083. doi: 10.1007/s11255-018-1803-3. Epub 2018 Jan 30.

Abstract

Sickle cell nephropathy is a major complication of sickle cell disease. It manifests in different forms, including glomerulopathy, proteinuria, hematuria, and tubular defects, and frequently results in end-stage renal disease (ESRD). Different pathophysiologic mechanisms have been proposed to explain the development of nephropathy in SCD, where hemolysis and vascular occlusion are the main contributors in the manifestations of this disease. Markers of renal injury, such as proteinuria and tubular dysfunction, have been associated with outcomes among patients with sickle cell nephropathy and provide means for early detection of nephropathy and screening prior to progression to renal failure. In small-sized clinical trials, hydroxyurea has demonstrated to be effective in slowing the progression to ESRD. Dialysis and renal transplantation represent the last resort for patients with sickle cell nephropathy. Nevertheless, despite the availability of diagnostic and therapeutic strategies, sickle cell nephropathy remains a challenging and under-recognized complication for patients with sickle cell disease.

摘要

镰状细胞肾病是镰状细胞病的主要并发症。它以不同形式表现出来,包括肾小球病、蛋白尿、血尿和肾小管缺陷,并常常导致终末期肾病(ESRD)。已经提出了不同的病理生理机制来解释镰状细胞病中肾病的发展,其中溶血和血管闭塞是该疾病表现的主要促成因素。肾损伤标志物,如蛋白尿和肾小管功能障碍,与镰状细胞肾病患者的预后相关,并为肾病的早期检测和在进展至肾衰竭之前进行筛查提供了手段。在小型临床试验中,羟基脲已证明可有效减缓向终末期肾病的进展。透析和肾移植是镰状细胞肾病患者的最后手段。然而,尽管有诊断和治疗策略,但镰状细胞肾病对镰状细胞病患者来说仍然是一个具有挑战性且未得到充分认识的并发症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验